Banook Acquires Fluidda – Major Step Forward in Respiratory Clinical Research
We are thrilled to announce that Fluidda has joined forces with Banook, a global leader in clinical trial services.
For nearly two decades, Fluidda has pioneered Functional Respiratory Imaging (FRI) to accelerate drug development and improve the lives of patients with respiratory diseases.
By combining Fluidda’s imaging and AI expertise with Banook’s global reach and operational excellence, we are creating a stronger, more comprehensive partner with a unique offering for pharmaceutical and biotech companies worldwide.
Together, we will continue to push the boundaries of science and technology to bring effective treatments to patients faster.
To learn more about Banook’s acquisition of Fluidda, read the press review
BREATHE THE AIR!
With one person dying every minute from a respiratory condition, patients with pulmonary diseases deserve better, faster and less costly treatments. At Fluidda, we are leading the way in a world where the quality of air is under stress.
Our aim is to optimize treatment pathways, reduce healthcare costs, bring therapies to the market faster and move toward value-based healthcare. Our FRI technology will help patients worldwide to breathe the air!
Are you a Healthcare company?
Fluidda can speed up your respiratory drug development or medical device development and derisk clinical trials.
Broncholab
Learn how Fluidda assists radiologists and pulmonologists with treatment optimization for respiratory patients. Fluidda offers respiratory solutions to optimize the treatment of your patient
FRI enables you to look inside the lung, by adding visualization and regional information to these measurements, therefore providing further insight into the regional functionality of the lung.
In clinical practice, physicians have to deal with an unmet need for improvement of current diagnostic tools. For personalized and precision treatment, an improved understanding of disease pathophysiology and complexity can be helpful in choosing the most suitable treatment approach. Especially in the difficult cases, it is essential to define the correct approach. Currently, this results in high healthcare costs for chronically ill patients.
Recent News >
Fluidda helps Firefighters
Californian firefighters are exposed to repeated, intense wildfire smoke, and the long term effects are still unknown. FiGHT is a non-profit charity campaign aiming at screening firefighters and first responders for lung diseases that might be present but are not yet reflected in standard of care (spirometry) or symptoms.
Fluidda’s Functional Respiratory Imaging technology combined with artificial intelligence allows patient-specific treatment to be assigned. Discover how Fluidda supports firefighters on https://www.jointhefight.info/